When and why should oral urea be used in the management of chronic hyponatremia?

When and Why to Use Oral Urea in Chronic Hyponatremia

Direct Answer

Oral urea is indicated as second-line therapy for chronic euvolemic hyponatremia (SIADH) when fluid restriction fails, typically at doses of 15–60 g/day, and is particularly valuable in resource-limited settings or when vaptans are contraindicated, unavailable, or poorly tolerated. 1, 2, 3

---

Primary Indication: SIADH Refractory to Fluid Restriction

• Approximately 50% of SIADH patients fail first-line fluid restriction (1–1.5 L/day), making second-line therapy necessary. 4
• Oral urea is equally effective to vaptans and superior to no treatment for raising serum sodium in SIADH, with a mean increase of 9.6 mmol/L across multiple studies. 1, 2
• Urea increases serum sodium by a mean of 9.08 mmol/L (95% CI 7.64–10.52) in patients with SIADH-related hyponatremia. 1

---

Dosing and Administration

• Standard dosing is 15–60 g/day orally, typically divided into 2–3 doses; a median dose of 30 g/day for 4 days is commonly used. 4, 5
• Higher cumulative doses are independently associated with greater sodium correction (β 0.03,95% CI 0.02–0.03 per gram). 5
• Urea can be combined with fluid restriction during the first 48 hours to enhance initial correction (β 1.81,95% CI 0.40–3.08), though this benefit diminishes after 2 days. 5

---

Clinical Factors Predicting Response

Factors Associated with Greater Sodium Rise

• Older age (β 0.09,95% CI 0.02–0.16 per year) 5
• Lower baseline serum sodium (β -0.65,95% CI -0.78 to -0.62 per mmol/L) 5
• Higher cumulative urea dose (β 0.03,95% CI 0.02–0.03 per gram) 5

Severity-Based Efficacy

• Severe hyponatremia (<120 mmol/L): mean increase 18.04 mmol/L (95% CI 13.68–22.39) 1
• Moderate hyponatremia (120–129 mmol/L): mean increase 7.86 mmol/L (95% CI 6.78–8.94) 1
• Mild hyponatremia (130–135 mmol/L): mean increase 8.00 mmol/L (95% CI 7.31–8.69) 1

---

Advantages Over Alternative Therapies

Compared to Vaptans

• Urea is non-inferior to tolvaptan (mean difference -1.96 mmol/L, 95% CI -4.59 to 0.66, P=0.1) but avoids vaptan-specific risks. 1
• Vaptans carry a 30-day safety limit and increased mortality risk with prolonged use in cirrhosis trials, whereas urea has been used safely for up to 1 year. 4, 1
• Urea costs significantly less than vaptans, making it preferable in resource-limited settings. 1, 2, 3

Compared to Fluid Restriction Alone

• Urea is statistically equivalent to fluid restriction (mean difference 0.81 mmol/L, 95% CI -0.93 to 2.55, P=0.4) but provides an alternative when restriction is impractical or poorly tolerated. 1

---

Safety Profile and Adverse Events

• No cases of osmotic demyelination syndrome (ODS) have been reported with oral urea in any published series. 1, 2, 6
• Urea protects against ODS in experimental models, making it safer than hypertonic saline for chronic correction. 6
• Adverse events are minor: poor palatability/dysgeusia is the most common complaint, leading to discontinuation in only 11% of cases. 1, 2, 5
• Overcorrection occurs in only 3% of treatment episodes, far lower than with hypertonic saline or vaptans. 5

---

Monitoring During Urea Therapy

• Check serum sodium every 4 hours initially, then daily once stable correction is achieved. 4
• Monitor serum urea: urea treatment increases serum urea by a mean of 31.66 mg/dL (95% CI 16.05–47.26). 1
• Adjust dose based on sodium response: if correction is inadequate after 24–48 hours, increase the daily dose by 15 g increments. 5

---

When NOT to Use Oral Urea

Absolute Contraindications

• Severe symptomatic hyponatremia (seizures, coma, GCS ≤8, respiratory distress) requires immediate 3% hypertonic saline, not oral urea. 4, 3
• Hypovolemic hyponatremia (urine sodium <30 mmol/L, clinical volume depletion) requires isotonic saline replacement, not urea. 4
• Cerebral salt wasting in neurosurgical patients requires hypertonic saline plus fludrocortisone; urea is inappropriate. 4

Relative Contraindications

• Hypervolemic hyponatremia (cirrhosis, heart failure) should be managed with disease-specific therapy and fluid restriction first; urea is not first-line. 7, 4
• Acute hyponatremia (<48 hours) with moderate symptoms may require faster correction than urea provides. 4

---

Practical Algorithm for Urea Use

Step 1: Confirm SIADH Diagnosis

• Serum sodium <135 mmol/L, serum osmolality <275 mOsm/kg, urine osmolality >100 mOsm/kg, urine sodium >40 mmol/L, clinical euvolemia, and exclusion of hypothyroidism/adrenal insufficiency. 4

Step 2: Trial Fluid Restriction

• Restrict fluids to 1–1.5 L/day for 48–72 hours; monitor serum sodium every 4 hours initially. 4

Step 3: Initiate Urea if Restriction Fails

• Start oral urea 30 g/day (15 g twice daily) if serum sodium remains <130 mmol/L after 48 hours of fluid restriction. 5
• Consider combining urea with continued fluid restriction during the first 48 hours for enhanced initial correction. 5

Step 4: Titrate Dose Based on Response

• If sodium rises <4 mmol/L in 24 hours, increase urea to 45 g/day. 5
• If sodium rises 4–6 mmol/L in 24 hours, continue current dose. 4
• If sodium rises >8 mmol/L in 24 hours, reduce dose by 15 g and consider liberalizing fluids. 4

Step 5: Transition to Maintenance

• Once serum sodium reaches 130–135 mmol/L, reduce urea to the lowest effective dose (typically 15–30 g/day) for long-term management. 1

---

Common Pitfalls to Avoid

• Do not use urea as first-line therapy; fluid restriction should be attempted first unless contraindicated. 4, 8
• Do not use urea in severe symptomatic hyponatremia; these patients require immediate hypertonic saline. 4, 3
• Do not assume all euvolemic hyponatremia is SIADH; exclude hypothyroidism (TSH), adrenal insufficiency (morning cortisol), and cerebral salt wasting (clinical hypovolemia) before starting urea. 4
• Do not use urea in hypovolemic patients; this worsens effective arterial volume and can precipitate renal failure. 4
• Do not combine urea with vaptans; there is no evidence for synergistic benefit and this increases cost without proven added efficacy. 1, 3

---

Special Populations

Cirrhosis

• Urea is not recommended for hypervolemic hyponatremia in cirrhosis; these patients require fluid restriction, diuretic adjustment, and disease-specific therapy. 7, 4
• If SIADH coexists with cirrhosis (rare), urea may be considered after excluding infection and optimizing cirrhosis management. 7

Neurosurgical Patients

• Do not use urea in post-craniotomy or subarachnoid hemorrhage patients; cerebral salt wasting is more common than SIADH and requires opposite therapy (volume expansion, not osmotic diuresis). 4

Elderly Patients

• Older age predicts greater sodium correction with urea (β 0.09 per year), requiring closer monitoring to avoid overcorrection. 5